Weak inhibitors protect cholinesterases from strong inhibitors (paraoxon): In vitro effect of ranitidine

Journal of Applied Toxicology

Volumn 25, Issue 1, 2005, Pages 60-67

  Petroianu, G A ^a   Arafat, K ^a   Schmitt, A ^b   Hasan, M Y ^a  

^a UNITED ARAB EMIRATES UNIVERSITY   (United Arab Emirates)

^b CENTRAL INSTITUTE OF MENTAL HEALTH   (Germany)

Author keywords

Cholinesterase; Paraoxon; Pralidoxime; Ranitidine

Indexed keywords

ACETYLCHOLINESTERASE; CHOLINESTERASE; CHOLINESTERASE INHIBITOR; METOCLOPRAMIDE; ORGANOPHOSPHATE; PARAOXON; RANITIDINE;

ARTICLE; BINDING AFFINITY; CALCULATION; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; ERYTHROCYTE; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; PHOTOMETRY; PLASMA; PRIORITY JOURNAL; PROTECTION;

ACETYLCHOLINESTERASE; BUTYRYLCHOLINESTERASE; CHOLINESTERASE INHIBITORS; CHOLINESTERASES; ERYTHROCYTES; HUMANS; INHIBITORY CONCENTRATION 50; PARAOXON; RANITIDINE;

EID: 13244255599     PISSN: 0260437X     EISSN: None     Source Type: Journal    
DOI: 10.1002/jat.1036     Document Type: Article

References (26)

1. Dart RC, Goldfrank LR, Chyka PA, Lotzer D, Woolf AD, McNally J, Snodgrass WR, et al. 2000. Combined evidence-based literature analysis and consensus guidelines for stocking of emergency antidotes in the United States. Ann. Emerg. Med. 36: 126-132.
2. Ellman GL, Courtney Kd, Andres Jr. V. 1961. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem. Pharmacol. 7: 88-95.
3. Galli A, Mantovani P, Pepeu G. 1984. Effect of ranitidine on ileal myenteric plexus preparation and on acetyl- and butyrylcholinesterase. Biochem. Pharmacol. 15: 1845-1850.
4. Grant SM, Langtry HD, Brogden RN. 1989. Ranitidine. An updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in peptic ulcer disease and other allied diseases. Drugs 37: 801-870.
5. Gwee MCE, Cheah LS. 1991. Antimuscarinic and anticholinesterase activity of cimetidine and ranitidine: clinically significant? Br. J. Clin. Pharmacol. 32: 260-261.
6. Hansen WE, Bertl S. 1983a. Inhibition of cholinesterases by ranitidine. Lancet 29: 235.
7. Hansen WE, Bertl S. 1983b. Inhibition of acetylcholinesterases - a relevant side effect of ranitidine? Z. Gastroenterol. 21: 164-167.
8. Jeyaratnam J. 1990. Acute pesticide poisoning: a major global health problem. World Health Stat. Q. 43: 139-144.
9. Johnson MK, Jacobsen D, Meredith TJ, Eyer P, Heath AJ, Ligtenstein DA, Marrs TC, et al. 2000. Evaluation of antidotes for poisoning by organophosphorus pesticides. Emerg. Med. 12: 22-37.
10. Karalliedde L. 1999. Organophosphourus poisoning and anaesthesia. Anaesthesia 54: 1073-1088.
11. Kounenis G, Koutsoviti-Papadopoulou M, Elezoglou V. 1994. Ketamine inhibits the anticholinesterase activity of ranitidine and physostigmine. Gen. Pharmacol. 25: 631-634.
12. Laine-Cessac P, Turcant A, Premel-Cabic A, Boyer J, Allain P. 1993. Inhibition of cholinesterases by histamine 2 receptor antagonist drugs. Res. Commun. Chem. Pathol. Pharmacol. 79: 185-193.
13. Levine R. 1991. Recognized and possible effects of pesticides in humans. In Handbook of Pesticide Toxiclogy. General Principles, vol. 1, Hayes WJ. Laws ER (eds). Academic Press: San Diego; 275-360.
14. Louis WJ, Mihaly GW, Hanson RG, Anderson A, McNeil JJ, Yeomans ND, Small wood RA 1981. Pharmacokinetic and gastric secretory studies of ranitidine in man. Scand. J. Gastroenterol. Suppl. 69: 11-17.
15. Namba T. 1971. Cholinesterase inhibition by organophosphorus compounds, and its clinical effects. Bull. WHO 44: 289-307.
16. Namba T, Nolte CT, Jackrel J, Grob D. 1971. Poisoning due to organophosphate insecticides: acute and chronic manifestations. Am. J. Med. 50: 457-492.
17. Peter JV, Cherian AM. 2000. Organic insecticides. Anaesth. Intens. Care 28: 11-21.
18. Petroianu G, Toomes LM, Petroianu A, Bergeler W, Rüfer R. 1998. Control of blood pressure, heart rate and haematocrit during high-dose intravenous paraoxon exposure in mini pigs. J. Appl. Toxicol. 18: 293-298.
19. Petroianu G, Hardt F, Toomes LM, Petroianu A, Bergeler W, Rüfer R. 2001. High-dose i.v. paraoxon exposure does not cause organophosphate-induced delayed neuropathy (OPIDN) in mini pigs. J. Appl. Toxicol. 21: 263-268.
20. Petroianu G, K Arafat, M Kosanovic, A Saleh, V Camasamudram, M Hassan. 2003a. In vitro protection of RBC acetylcholinesterase by metoclopramide from inhibition by organophosphates (paraoxon and mipafox). J. Appl. Toxicol. 23: 447-451.
21. Petroianu G, Kuehn F, Thyes C, Ewald V, Missler A. 2003b. In vitro protection of plasma cholinesterases by metoclopramide from inhibition by paraoxon. J. Appl. Toxicol. 23: 75-79.
22. Petroianu G, MY Hassan, M Kosanovic, V Camasamudram, A Saleh. 2003c. Metoclopramide protection of cholinesterase from paraoxon inhibition. Vet. Hum. Toxicol. 45: 251-253.
23. Van Helden HP, Busker RW, Melchers BPC, Bruijnzeel PLB. 1996. Pharmacological effects of oximes: how relevant are they? Arch. Toxicol. 70: 779-786.
24. Van Kampen EJ, Zijlstra WG. 1961. Standardization of hemoglobinometry II. The hemoglobincyanide method. Clin. Chim. Acta 6: 538-544.
25. Worek F, Mast U, Kiderlen D, Diepold C, Eyer P. 1990. Improved determination of acetylcholinesterase activity in human whole hlood. Clin. Chim. Acta 288: 73-90.
26. Zoch E. 1971. Die Wirkung organischer Phosphorsäureester bzw. Phosphorsäureester auf verseil. Arzneim. Forsch. 21: 181-187.